Arbutus Biopharma Corp Debt Securities, Available-for-sale, Amortized Cost, Noncurrent
Arbutus Biopharma Corp (ABUS) had Debt Securities, Available-for-sale, Amortized Cost, Noncurrent of $2.93 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent · last filed 2025-03-27
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $2.93M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $6.27M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $38.13M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $56.77M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Noncurrent |
|---|---|
| 2024-09-30 | $2.93M 10-Q · filed 2024-11-06 |
| 2023-12-31 | $6.27M 10-K · filed 2025-03-27 |
| 2022-12-31 | $38.13M 10-K · filed 2024-03-05 |
| 2022-09-30 | $56.77M 10-Q · filed 2022-11-09 |
| 2021-12-31 | $35.77M 10-K · filed 2023-03-02 |
| 2021-06-30 | $42.92M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |